March 11, 2022 – Medigen, Inc’s Dr. Irina Tretyakova and Dr. Peter Pushko in collaboration with Dr. John Vasilakos (Kindeva) and Dr. Tomai (3M) have published the manuscript titled Live-Attenuated VEEV Vaccine Delivered by iDNA using Microneedles is Immunogenic in Rabbits in Frontiers in Tropical Diseases, 2 Mar 2022.
The authors demonstrate induction of neutralizing antibody in rabbits vaccinated with a novel naked DNA vaccine that encodes live-attenuated Venezuelan equine encephalitis virus (VEEV). High titers of neutralizing antibodies to VEEV were detected following a single intradermal administration of Medigen’s VEEV vaccine with Kindeva’s hollow microneedle device.
The findings highlight the vaccine potential of naked DNA administered intradermally without the need for electroporation. Thus, combination of iDNA vaccine and hollow microneedle device improves vaccination with live-attenuated vaccines by providing simple, single-dose immunization.
About Kindeva Drug Delivery
Kindeva is a global contract development manufacturing organization focused on drug-device combination products. Kindeva develops and manufactures products across a broad range of complex drug-delivery formats, including autoinjectors, inhalers, transdermal patches, and microneedles. Its service offering spans early-stage feasibility through commercial scale drug product fill-finish, container closure system manufacturing, and drug-device product assembly. Kindeva serves a global client base in the commercial and health security markets from its nine manufacturing and research and development facilities located in the U.S. and U.K. For more information, please visit www.kindevadd.com.
About Medigen, Inc.
Medigen is an independent prophylactic and therapeutic vaccine company founded in 2004. The company is headquartered in Frederick, Maryland. Medigen develops vaccines against emerging infectious diseases. Medigen vaccines are based on unique, proprietary technologies designed to elicit safe, natural immune responses for efficient, long-term immunity. Proprietary vaccine technologies include VLPs, RNA vectors, iDNA, and reassortant virus. www.medigen-usa.com